acquired
Stage
2012
Founded
1
Investors
About
Eternygen was a German biotech company focused on discovering and developing novel therapeutics for metabolic diseases, particularly targeting SMCT1 for non-alcoholic steatohepatitis (NASH). The company was acquired by Novo Nordisk in 2019.
Explore Eternygen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.